Tehran University of Medical Sciences Iranian Journal of Microbiology 2008-3289 15 3 2023 06 16 456 461 EN Nasrin Amirrajab Department of Laboratory Sciences, School of Allied Medical Sciences, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran Seyed Amin Ayatollahi Mousavi Department of Parasitology and Mycology, School of Medicine, Medical Mycology Research Center, Kerman University of Medical Sciences, Kerman, Iran Behrooz Taheri Department of Laboratory Sciences, School of Allied Medical Sciences, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran Samira Salari Department of Parasitology and Mycology, School of Medicine, Medical Mycology Research Center, Kerman University of Medical Sciences, Kerman, Iran Noor Ali Ahmadi Sarsahra Department of Parasitology and Mycology, School of Medicine, Medical Mycology Research Center, Kerman University of Medical Sciences, Kerman, Iran 2022 10 04 2023 03 07 Background and Objectives: The aim of this study was to investigate the in vitro antifungal potency of the moronecidin-like peptide against Candida albicans, Candida glabrata, and Candida tropicalis. Materials and Methods: To evaluate the antifungal effect of moronecidin-like peptide, the protocol presented in CLSI M27-A3 and CLSI M27-S4 was used and the minimum inhibitory concentration was determined. Results: The minimum inhibitory effect of moronecidin-like peptide composition was 8 µg/ml for Candida tropicalis and Candida albicans and 32 µg/ml for Candida glabrata. The MIC of nystatin was determined to be 1.25 µg/ml for Candida glabrata and Candida albicans and 0.625 µg/ml for Candida tropicalis strains. The MFC composition of the moronecidin-like peptide was determined for Candida tropicalis and Candida albicans strains 8 µg/ml and for Candida glabrata strain 64 µg/ml. The results of cytotoxicity and hemolysis of the moronecidin peptide test on macrophage showed that moronecidin peptide has no cytotoxicity and toxicity properties. Conclusion: According to the results of the present study, the moronecidin-like peptide could be a new strategy in the treatment of infections caused by Candida strains. The discovery of the exact mechanism of which requires extensive clinical studies in this field. https://ijm.tums.ac.ir/index.php/ijm/article/view/3928 https://ijm.tums.ac.ir/index.php/ijm/article/download/3928/1588